Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal irinotecan + fruquintinib + sintilimab for second-line advanced HER2-negative gastric cancer
ChiCTR2400085651Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nanoliposomal irinotecan, fruquintinib and sintilimab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by First Affiliated Hospital of Nanchang University. Primary endpoint: Overall response rate. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecanfruquintinibsintilimab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400085651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085651.